Butyric Acid

Butyric Acid

SCHEMBL1728044

CCCC(=O)O.CCCCO

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.68
HDAC3 O15379 1/20 0.68
HDAC1 Q13547 1/20 0.68
HDAC2 Q92769 1/20 0.68
HDAC8 Q9BY41 1/20 0.68
AKR1B1 P15121 1/20 0.59
ALDH1A1 P00352 3/20 0.58
CAMK2A Q9UQM7 1/20 0.57
GPR84 Q9NQS5 8/20 0.56
PPARG P37231 7/20 0.56
PPARD Q03181 7/20 0.56
PPARA Q07869 7/20 0.56
HDAC11 Q96DB2 5/20 0.56
TSHR P16473 4/20 0.56
PTPN1 P18031 3/20 0.56
TLR2 O60603 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
FABP4 P15090 2/20 0.56
FFAR1 O14842 2/20 0.56
FFAR4 Q5NUL3 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL11355516 0.97 FFAR3 (0.65) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL7777837 0.97 FFAR3 (0.65) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL27959816 0.95 FFAR3 (0.62) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL28175671 0.95 FFAR3 (0.62) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL8603917 0.95 FFAR3 (0.62) FFAR3HDAC3HDAC1HDAC2HDAC8
Heptane SCHEMBL28449904 0.95 GPR84 (0.65) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL17078357 0.93 FFAR3 (0.59) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL6684753 0.93 FFAR3 (0.59) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL8727435 0.93 FFAR3 (0.59) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL30473397 0.92 FFAR3 (0.65) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080183011-A1 Process for preparation of perindopril erbumine in alpha crystalline form IPCA LABORATORIES LIMITED 2008-07-31 US claimed
EP-0879058-B1 MIXTURES DERIVED FROM GRAINS OF EUGENIA JAMBOLANA LAMARCK, PREPARATION AND USE OF SAID MIXTURES AND SOME OF THEIR CONSTITUENTS AS MEDICAMENTS INST MALGACHE DE RECH S APPLIQ (MG) 2001-06-06 EP claimed
US-11584914-B2 Processes for producing organic solvents using Clostridium saccharoperbutylacetonicum BIOCLEAVE LIMITED (GB) 2023-02-21 US disclosed
US-20210189325-A1 PROCESSES INVOLVING CLOSTRIDIUM SACCHAROPERBUTYLACETONICUM BIOCLEAVE LIMITED (GB) 2021-06-24 US disclosed
EP-3694983-A1 PROCESSES INVOLVING CLOSTRIDIUM SACCHAROPERBUTYLACETONICUM Biocleave Limited (GB) 2020-08-19 EP disclosed
CN-104293840-B A method of improving esterification by lipase reaction vigor and recycling 丰益(上海)生物技术研发中心有限公司 2019-06-07 CN disclosed
WO-2019073254-A1 PROCESSES INVOLVING CLOSTRIDIUM SACCHAROPERBUTYLACETONICUM GREEN BIOLOGICS LIMITED (GB) 2019-04-18 WO disclosed
CN-104955938-B Recombinant microorganism and its production method comprising NADPH dependent enzymes 朗泽科技新西兰有限公司 2018-03-02 CN disclosed
EP-2630247-B1 PRODUCTION OF BUTANOL FROM CARBON MONOXIDE BY A RECOMBINANT MICROORGANISM LANZATECH NEW ZEALAND LTD (NZ) 2017-03-15 EP disclosed
EP-3066069-A1 METHOD FOR SYNTHESISING ESTERS AND CATALYST FOR SAID SYNTHESIS Pivert (FR) 2016-09-14 EP disclosed
US-9359611-B2 Recombinant microorganism and methods of production thereof LANZATECH NEW ZEALAND LIMITED (NZ) 2016-06-07 US disclosed
WO-2003060113-A1 BIOREACTOR SILBIOTEC DUE S.A. (LU) 2003-07-24 WO disclosed
US-5425422-A Injecting deasphalted oil into well, soaking to solubilize deposits, resuming oil production NORANDA INC. (CA) 1995-06-20 US disclosed
US-4954483-A BACTERICIDE, ANIMAL GROWTH PROMOTER GRUPPO LEPETIT, S.P.A. (IT) 1990-09-04 US disclosed
EP-0216775-B1 CARBOXYLIC ACID ESTER DERIVATIVES OF DEGLUCOTEICOPLANIN GRUPPO LEPETIT S.p.A. (IT) 1989-05-03 EP disclosed
EP-0216775-A1 CARBOXYLIC ACID ESTER DERIVATIVES OF DEGLUCOTEICOPLANIN. LEPETIT SPA (IT) 1987-04-08 EP disclosed
EP-0062919-B1 INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1986-07-30 EP disclosed
WO-1986000075-A1 CARBOXYLIC ACID ESTER DERIVATIVES OF DEGLUCOTEICOPLANIN GRUPPO LEPETIT S.P.A. (IT) 1986-01-03 WO disclosed
EP-0062919-A1 Indole derivatives, process for their preparation and pharmaceutical compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1982-10-20 EP disclosed
US-3956260-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080183011-A1 Process for preparation of perindopril erbumine in alpha crystalline form ACE, REN, ADH1C FFAR3 1282/4885HDAC3 816/4885HDAC1 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.